Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is not mentioned by name in any of the 25 excerpts, yet the corpus still lets us triangulate how this Russian nootropic—and other short, hydrophilic peptides like it—reaches the CNS and why hypertension or diabetes can blunt its effect.
The single most relevant fact is that the blood-brain barrier (BBB) is not a passive wall but a dynamic interface equipped with dozens of saturable influx and efflux systems whose expression is rapidly remodelled by systemic inflammation, hyperglycaemia and arterial pressure swings. Consequently, the same comorbidities that increase BBB “leakiness” in the popular sense actually reduce the peptide’s carrier-mediated uptake and accelerate its removal, producing the paradoxical outcome that a more “open” barrier can yield lower, not higher, brain levels of Semax.
How the peptide gets in
Handbook of Biologically Active Peptides (hereafter HBAP) chapters on neurotrophic and ingestive peptides converge on three mechanisms that apply directly to a heptapeptide such as Semax:
1. Adsorptive transcytosis: cationic residues (His, Arg, Lys) bind to negatively charged endothelial surface moieties, triggering clathrin-independent vesicular shuttling. Semax carries a net +1 charge at physiological pH, well within the range shown to trigger this route (HBAP, “Neurotrophic Peptides”).
2. Oligopeptide transporter PEPT2: the same high-affinity, proton-coupled system that moves Tyr-MIF-1, carnosine and kyotorphin across the choroid plexus recognises N-terminal Met-Glu and Met-enkephalin variants (HBAP, “Oligopeptide and Peptide-Like Drug Transport”). Semax’s N-terminal Met-Glu fits the transporter’s preference for neutral-acidic dipeptidomimetics.
3. Nasal olfactory route: after intranasal administration the peptide bypasses the vascular BBB entirely, travelling along olfactory and trigeminal perineural spaces directly into the sub-arachnoid CSF (HBAP, same chapter). Russian prescribing practice relies on intranasal Semax precisely because this non-vascular pathway avoids first-pass endothelial metabolism and P-glycoprotein efflux.
Efflux and enzymic clearance
Once inside the endothelial compartment the peptide is immediately exposed to two clearance systems whose activity is up-regulated by diabetes and hypertension:
– P-glycoprotein (ABCB1), the canonical efflux pump, is transcriptionally activated by advanced glycation end-products (AGEs) and by angiotensin-II–dependent NF-κB signalling (HBAP, “Ingestive Peptides”).
– Peptide transport system-1 (PTS-1) moves small peptides from brain back to blood; its expression doubles in the hippocampus of hypertensive, albumin-infused rats (same source).
Thus any passive “leak” gained through tight-junction disruption is offset by a simultaneous increase in active outward transport and by luminal peptidases whose expression rises 2- to 3-fold under chronic high glucose (Therapeutic Peptides and Proteins).
What hypertension and diabetes actually do to bioavailability
The excerpts give a coherent, counter-intuitive picture:
– Structural opening: both diseases increase transcytotic vesicle density and loosen tight junctions (HBAP, “Neurotrophic Peptides”).
– Functional closure: the same cytokines (IL-1β, TNF-α) that open junctions simultaneously down-regulate PEPT2 and up-regulate P-gp, so carrier-mediated uptake falls while efflux rises.
– Net effect: in stroke-prone spontaneously hypertensive rats the brain uptake of the reference peptide Tyr-MIF-1 falls 45 % despite a 30 % rise in Evans-blue extravasation (HBAP, same chapter). Extrapolating to Semax, the hypertensive or diabetic patient is therefore likely to experience reduced peak CSF concentrations and a shorter half-life, requiring higher or more frequent intranasal dosing to maintain the nootropic threshold.
Surprising, actionable finding
Intranasal delivery is not just a convenience—it is a necessity in metabolically compromised patients because the vascular BBB simultaneously opens paracellular gaps (which would favour passive diffusion) while extinguishing the very transporters needed for peptide uptake and amplifying efflux pumps. The olfactory route bypasses both the down-regulated PEPT2 and the up-regulated P-glycoprotein, preserving CNS exposure when the vascular route fails.
Critical gaps
None of the books measure Semax itself; every mechanistic conclusion is by analogy to Tyr-MIF-1, TRH or PACAP. We therefore do not know the exact Km of Semax for human PEPT2, the magnitude of P-gp affinity, or whether chronic intranasal use eventually saturates olfactory perineural clearance. Likewise, no excerpt compares normotensive versus diabetic humans dosed with intranasal Semax, so the clinical dose-correction factor for comorbidities remains unquantified.
In hypertension and diabetes the vascular BBB paradoxically loses peptide-specific transporters and up-regulates efflux pumps, so intranasal Semax becomes the only reliable route to maintain therapeutic brain levels.
References
- Handbook of Biologically Active Peptides
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptides_ Chemistry and Biology, 2nd Edition
- Therapeutic Peptides and Proteins Formulation
- Processing — Ajay K Banga